News
-
NEW APPROVAL | FDA Endorses Piasky for Paroxysmal Nocturnal Hemoglobinuria
Piasky, developed by Roche, is a monoclonal antibody that targets complement protein C5. Crovalimab binds to C5 to prevent its cleavage, thus preventing the formation of the membrane attack complex…
Read More » -
CAD | Enjaymo Not Cost-Effective at Current Price, According to US Study
This conclusion was drawn from a cost-effectiveness study utilizing data from the Phase 3 CARDINAL clinical trial, which backed the treatment’s approval for CAD patients with a recent history of…
Read More » -
SPOTLIGHT | TIF Wins Prestigious HemaSphere Award at EHA2024
The HemaSphere Awards were presented by the official journal of the European Hematology Association (EHA) during Europe’s most important scientific event in the field of Haematology, EHA2024 Hybrid Congress, held…
Read More » -
NEW PUBLICATION | Nutrition in Thalassaemia: A Guide for Patients, Families, and Caregivers
The guide encompasses: An overview of the nutritional needs specific to people with thalassaemia Methods for nutritional assessment Detailed explanations of nutrients particularly important for thalassaemia patients Insights into how…
Read More » -
-
TIF STUDY | Patient and Caregiver Perceptions of Thalassaemia Care in 2023
The study revealed that most patients with thalassaemia are receiving adequate treatment, including regular blood transfusions, chelation therapy, proper monitoring, and suitable imaging. Out of 2082 participants, 79.5% began transfusion…
Read More » -
WHA77 SIDE EVENT | Access to Novel Therapies Globally: Opportunities and Challenges
The Side Event entitled “Access to Novel Therapies Globally: Opportunities and Challenges” is set to take place Friday, 31 May 2024, from 10:00 to 13:30, at the International Museum of…
Read More » -
-
-
